Browsing by Author "Muley, T."

Now showing 1 - 7 of 7

Some of the metrics are blocked by your
consent settings
Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer
(2021)
Mountzios, G.
;
Samantas, E.
;
Senghas, K.
;
Zervas, E.
;
Krisam, J.
;
Samitas, K.
;
Bozorgmehr, F.
;
Kuon, J.
;
Agelaki, S.
;
Baka, S.
;
Athanasiadis, I.
;
Gaissmaier, L.
;
Elshiaty, M.
;
Daniello, L.
;
Christopoulou, A.
;
Pentheroudakis, G.
;
Lianos, E.
;
Linardou, H.
;
Kriegsmann, K.
;
Kosmidis, P.
;
El Shafie, Rami
;
Kriegsmann, M.
;
Psyrri, A.
;
Andreadis, C.
;
Fountzilas, E.
;
Heussel, C.-P.
;
Herth, F. J.
;
Winter, H.
;
Emmanouilides, C.
;
Oikonomopoulos, G.
;
Meister, M.
;
Muley, T.
;
Bischoff, H.
;
Saridaki, Z.
;
Razis, E.
;
Perdikouri, E.-I.
;
Stenzinger, A.
;
Boukovinas, I.
;
Reck, M.
;
Syrigos, K.
;
Thomas, M.
;
Christopoulos, P.
The advanced lung cancer inflammation index [ALI: body mass index × serum albumin/neutrophil-to-lymphocyte ratio (NLR)] reflects systemic host inflammation, and is easily reproducible. We hypothesized that ALI could assist guidance of non-small-cell lung cancer (NSCLC) treatment with immune checkpoint inhibitors (ICIs).
Some of the metrics are blocked by your
consent settings
Clinical and laboratory predictors of immune checkpoint inhibitor efficacy in non-small cell lung cancer
(2018)
Christopoulos, P.
;
Kohlhäufl, J.
;
Bozorgmehr, F.
;
Kuon, J.
;
Schneider, M.
;
Neumann, O.
;
Liersch, S.
;
Heussel, C.
;
Winter, H.
;
Herth, F.
;
Rieken, S.
;
Muley, T.
;
Meister, M.
;
Bischoff, H.
;
Lasitschka, F.
;
Stenzinger, A.
;
Thomas, M.
Some of the metrics are blocked by your
consent settings
Real-world implementation of sequential targeted therapies for EGFR-mutated NSCLC
(2019)
Christopoulos, P.
;
Volckmar, A.-L.
;
Bozorgmehr, F.
;
Magios, N.
;
Kuon, J.B.
;
Kirchner, M.
;
Kazdal, D.
;
Endris, V.
;
Bochtler, T.
;
Herth, F.J.F.
;
Heussel, C.-P.
;
Winter, H.
;
Muley, T.
;
Meister, M.
;
Fischer, J.R.
;
Rieken, S.
;
Faehling, M.
;
Bischoff, H.
;
Stenzinger, A.
;
Thomas, M.
Some of the metrics are blocked by your
consent settings
Retrospective study of paclitaxel in advanced therapy lines in the treatment of SCLC
(2018)
von Eiff, D.
;
Bozorgmehr, F.
;
Christopoulos, P.
;
Chung, I.
;
Bernhardt, D.
;
Rieken, S.
;
Liersch, S.
;
Muley, T.
;
Kobinger, S.
;
Thomas, M.
;
Steins, M.
Some of the metrics are blocked by your
consent settings
Risk stratification of EGFR+ lung cancer diagnosed with panel-based next-generation sequencing
(2020)
Christopoulos, P.
;
Kirchner, M.
;
Roeper, J.
;
Saalfeld, F.
;
Janning, M.
;
Bozorgmehr, F.
;
Magios, N.
;
Kazdal, D.
;
Volckmar, A. L.
;
Brückner, L. M.
;
Bochtler, T.
;
Kriegsmann, M.
;
Endris, V.
;
Penzel, R.
;
Kriegsmann, K.
;
Eichhorn, M.
;
Herth, F. J. F.
;
Heussel, C. P.
;
El Shafie, Rami A.
;
Schneider, M. A.
;
Muley, T.
;
Meister, M.
;
Faehling, M.
;
Fischer, J. R.
;
Heukamp, L.
;
Schirmacher, P.
;
Bischoff, H.
;
Wermke, M.
;
Loges, S.
;
Griesinger, F.
;
Stenzinger, A.
;
Thomas, M.
Panel-based next-generation sequencing (NGS) is increasingly used for the diagnosis of EGFR-mutated non-small-cell lung cancer (NSCLC) and could improve risk assessment in combination with clinical parameters.
Some of the metrics are blocked by your
consent settings
Technical performance and diagnostic utility of the new Elecsys (R) neuron-specific enolase enzyme immunoassay
(2003)
Muley, T.
;
Ebert, W.
;
Stieber, P.
;
Raith, H.
;
Holdenrieder, S.
;
Nagel, D.
;
Fürst, Heinrich
;
Roth, H. J.
;
Luthe, Hilmar
;
Blijenberg, B. G.
;
Gurr, E.
;
Uhl, W.
;
von Pawel, J.
;
Drings, P.
This international multicenter study was designed to evaluate the technical performance of the new double-monoclonal, single-step Elecsys neuron-specific enolase (NSE) enzyme immunoassay (EIA) and to assess its utility as a sensitive and specific test for the diagnosis of small-cell lung cancer (SCLC). Intra and interassay coefficients of variation, determined in five control or serum specimens in six laboratories, ranged from 0.7 to 5.3 (interlaboratory median: 1.3%) and from 1.3 to 8.5 (interlaboratory median: 3.4%), respectively. Laboratory-to-laboratory comparability was excellent with respect to recovery and interassay coefficients of variation. The test was linear between 0.0 and 320 ng/ml (highest measured concentration). There was a significant correlation between NSE concentrations measured using the Elecsys NSE and the established Cobas Core NSE EIA II in all subjects (n=723) and in patients with lung cancer (n=333). However, NSE concentrations were systematically lower (approximately 9%) with the Elecsys NSE than with the comparison test. Based on a specificity of 95% in comparison with the group suffering from benign lung diseases (n=183), the cutoff value for the discrimination between malignant and benign conditions was set at 21.6 ng/ml. NSE was raised in 73.4% of SCLC patients (n=188) and was significantly higher (p<0.01) in extensive (87.8%) as opposed to limited disease (56.7%). NSE was also elevated in 16.0% of the cases with non-small cell lung cancer (NSCLC, n=374). It is concluded that the Elecsys NSE EIA is a reliable and accurate diagnostic procedure for the measurement of NSE in serum samples. The special merits of this new assay are the wide measuring range (according to manufacturers declaration up to 370 ng/ml) and a short incubation time of 18 min.
Some of the metrics are blocked by your
consent settings
TP53 mutations impair overall survival of TKI-treated patients with oncogene-driven NSCLC
(2018)
Christopoulos, P.
;
Kirchner, M.
;
Bozorgmehr, F.
;
Endris, V.
;
Elsayed, M.
;
Magios, N.
;
Volckmar, A.-L.
;
Penzel, R.
;
Herth, F.J.F.
;
Heussel, C.P.
;
Winter, H.
;
Muley, T.
;
Meister, M.
;
Fischer, J.R.
;
Rieken, S.
;
Lasitschka, F.
;
Bischoff, H.
;
Schirmacher, P.
;
Thomas, M.
;
Stenzinger, A.